Webcasts
- October 14, 2024 - TG4001+Avelumab vs Avelumab Single-Agent Phase II Update
- September 20, 2023 - 2023 Half-year results and business update
- May 5, 2023 - New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- March 16, 2023 - 2022 Full-year results and business update
- September 27, 2022 - Transgene R&D Day (Paris, France)
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- November 12, 2020 - Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
Financial calendar
- March 27, 2024 - 2023 Fiscal Year Results
- May 14, 2024 - First Quarter 2024 Financial Results
- May 15, 2024 - Annual Shareholders’ Meeting
- September 24, 2024 - First Half 2024 Financial Results
- November 7, 2024 - Third Quarter 2024 Financial Results
Investor events
- January 15, 2024 - Oddo BHF Forum – January 15 & 16, 2024
- January 30, 2024 - Invest Securities Biomed Forum – January 30, 2024
- April 5, 2024 - Investor Access Event – April 5, 2024
- April 16, 2024 - Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 16, 2024
- June 6, 2024 - Oddo BHF Nextcap Forum – June 6, 2024
- September 17, 2024 - HealthTech Innovation Days (HTID) – Paris – September 17-18, 2024
- October 15, 2024 - Investor Access Forum, October 15 & 16, 2024
